Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

1595 - Serum Netrin-1 as a Biomarker for Colorectal Cancer Detection

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Translational Research

Tumour Site

Presenters

Jinzhou Zhu

Citation

Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239

Authors

J. Zhu1, L. Xi2, A. Wu1, X. Ma3, J. Zhang4

Author affiliations

  • 1 Department Of Gastroenterology, The First Affiliated Hospital of Soochow University, 215006 - Suzhou/CN
  • 2 Gastroenterology, The First Affiliated Hospital of Soochow University, 215006 - Suzhou/CN
  • 3 Department Of General Surgery, Suqian Affiliated Hospital of Xuzhou Medical University, 223800 - Suqian/CN
  • 4 Department Of Gastrointestinal Surgery, China-Japan Union Hospital of Jilin University, 130033 - Changchun/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1595

Background

Recent evidence supported that netrin-1 involves in colorectal carcinogenesis. This study was to evaluate the performance of serum netrin-1 for detection of colorectal cancer (CRC) in both a clinical set and a screening set.

Methods

A total of 115 consecutive patients with CRC and matched healthy controls were included in Clinical Set. Fifty subjects with CRC, 50 subjects with advanced adenoma (AA), and 150 matched control participants free of neoplasia were included in Screening Set. Circulating levels of netrin-1 were evaluated with commercial ELISA kits.

Results

In Clinical set, subjects with CRC presented higher levels of serum netrin-1 (513.9 ± 22.6 pg/mL) than controls (347.8 ± 20.3 pg/mL, p < 0.0001). Similar in Screening set, serum levels of netrin-1 was higher in CRC (644.5 ± 37.0 pg/mL), in comparison with controls (407.7 ± 14.8 pg/mL, p < 0.0001) and AA (416.5 ± 18.5 pg/mL, p < 0.0001). However, there was no difference between controls and AA (p = 0.752). Compared with the low netrin-1 group, the high group presented increased risk of CRC (Clinical set: OR = 4.300 [95% CI 2.473 – 7.477], p < 0.001); Screening set: OR = 7.731 [95% CI 3.618 – 16.519], p < 0.001). ROC curve of netrin-1 was developed to detect CRC (Clinical set: AUC 0.703 [95% CI 0.636 – 0.770]; Screening set: AUC 0.759 [95% CI 0.680 – 0.837]).Table: 147P

Study population characteristics

Clinical setScreening set
ControlsCRCControlsAACRC
Number1151151505050
Netrin-1 levels (pg/ml)347.8 ± 20.3*513.9 ± 22.6*407.7 ± 14.8#416.5 ± 18.5^644.5 ± 37.0#^
Age (years)53.8 ± 8.755.9 ± 9.154.2 ± 9.251.9 ± 10.055.8 ± 9.6
Sex
Male92921113737
Female2323391313
BMI (kg/m2)22.8 ± 3.024.6 ± 3.922.4 ± 2.923.1 ± 3.123.7 ± 3.1
WHR0.89 ± 0.080.92 ± 0.060.88 ± 0.080.94 ± 0.090.99 ± 0.07
TNM stage
I1610
II4322
III4213
IV145
Location
Colon8334
Rectum3216

Data are mean ± SD for continuous variables.

*

p < 0.001; #p < 0.001; p < 0.001. AA, advanced adenomas; BMI, body mass index; WHR, waist-to-hip circumference ratio.

Conclusions

It suggests netrin-1 as a potential biomarker in the screening and detection of CRC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The First Affiliated Hospital of Soochow University.

Funding

Jiangsu Provincial Key Research and Development Plan (No. BE2018659) and Provincial Key Laboratory Program of Higher Education (No. KJS1867).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.